What is the next augmentation approach for a patient with obsessive‑compulsive disorder who is currently taking sertraline 300 mg daily?

Augmentation Strategy for OCD on Sertraline 300 mg

For a patient with OCD on sertraline 300 mg who has not achieved adequate response, the best next step is augmentation with CBT if available, or pharmacological augmentation with aripiprazole or risperidone as first-line antipsychotic options, with memantine or lamotrigine as alternative glutamatergic agents. 1

Initial Considerations Before Augmentation

Before proceeding with augmentation, ensure the patient has received an adequate trial:

• Duration: The patient should have been on sertraline for at least 8-12 weeks at the current dose 1
• Dose optimization: At 300 mg daily, the patient is already above the FDA-approved maximum of 200 mg/day 2, though higher doses have been studied in treatment-resistant OCD 3
• Note: While sertraline doses up to 400 mg/day have been evaluated in research settings for non-responders, the evidence shows only modest additional benefit with higher doses 3

Recommended Augmentation Hierarchy

First-Line: Cognitive Behavioral Therapy (CBT)

• CBT augmentation produces larger effect sizes than antipsychotic augmentation (specifically superior to risperidone in head-to-head comparison) 1
• This should be the preferred option when available and when the patient can tolerate exposure therapy 1

Second-Line: Antipsychotic Augmentation

Aripiprazole or Risperidone are the most evidence-based antipsychotic options:

• Meta-analyses demonstrate efficacy for both risperidone and aripiprazole in SSRI-resistant OCD 1
• Aripiprazole is supported by multiple RCTs and recent systematic reviews as a top-tier choice 4, 5
• Risperidone has robust evidence from 7 RCTs 5
• Critical limitation: Only one-third of SSRI-resistant OCD patients show clinically meaningful response to antipsychotic augmentation 1

Important safety considerations:

• Use low-to-medium doses for a maximum of 3 months 6
• Mandatory discontinuation if no response 6
• Monitor closely for weight gain and metabolic dysregulation 1
• Quetiapine should be avoided—it was significantly inferior to fluoxetine plus clomipramine in the only head-to-head RCT 1

Third-Line: Glutamatergic Agents

Memantine has the strongest evidence among glutamatergic options:

• Multiple RCTs demonstrate efficacy for SSRI augmentation in treatment-resistant OCD 1
• A 2023 network meta-analysis identified memantine as the most effective augmentation agent with moderate certainty of evidence 4
• Recent systematic review supports memantine as a top-tier recommendation 5

Lamotrigine is another well-supported option:

• Backed by moderate certainty of evidence 4
• Recommended in recent systematic reviews alongside memantine and aripiprazole 5

N-acetylcysteine has the largest evidence base among glutamatergic agents:

• Three out of five RCTs demonstrated superiority to placebo 1
• Generally well-tolerated with favorable safety profile 1

Fourth-Line: Clomipramine Augmentation

Clomipramine plus SSRI showed efficacy in the only double-blind RCT comparing augmentation strategies:

• Fluoxetine plus clomipramine was significantly superior to fluoxetine plus quetiapine 1
• Major safety concern: Risk of severe and potentially life-threatening events including seizures, cardiac arrhythmias, and serotonin syndrome due to drug-drug interactions that increase blood levels of both medications 1
• This combination requires careful monitoring and should be reserved for refractory cases 1

Alternative Strategies to Consider

Switching to a different SSRI or trial of an SNRI are valid options before augmentation 1, though at 300 mg of sertraline, augmentation is more appropriate than switching.

Mirtazapine augmentation showed promise in a 2023 RCT, with 40.9% of patients achieving ≥35% reduction in YBOCS scores versus 4.3% with placebo 7, though this requires replication.

Common Pitfalls to Avoid

• Do not use quetiapine as first-line antipsychotic augmentation—it was inferior in direct comparison trials 1
• Do not continue antipsychotic augmentation beyond 3 months without clear response 6
• Do not combine clomipramine with sertraline without careful consideration of drug interactions and close monitoring for serotonin syndrome 1
• Ensure adequate trial duration before declaring treatment failure—the effect of time on SSRI monotherapy (6 months) was the most important factor associated with response in augmentation trials 1

Predictors of Response

Patients with comorbid tics or schizotypal disorder may have better response to antipsychotic augmentation 6. Meta-regression analysis shows that augmentation agents demonstrate significantly better symptom reduction in SRI-refractory OCD compared to non-refractory cases 4.